Page 87 - Merck Sharp News Today

NICE Recommends MSD’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for Routine Commissioning for First-Line Treatment of Adults with Untreated Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)[1]    LONDON, January 6, 2022 – Today, MSD (Merck Sharp & Dohme) (trad...

Biosimilar Market Share in Europe 2022-2027: Industry Trends, Size, Growth, Opportunity and Forecast

Biosimilar Market Share in Europe 2022-2027: Industry Trends, Size, Growth, Opportunity and Forecast

Pfizers antiviral drug Paxlovid, which contains a combination of PF-07321332 and ritonavir, has been approved by the MHRA for use in those with mild to moderate COVID-19 at risk of developing more severe disease.

Paxlovid can cut the risk of hospitalisation in vulnerable adults by 89%, a clinical trial suggests.

/PRNewswire/ -- The "Investigation Report on Chinas Metformin Market 2021-2025" report has been added to ResearchAndMarkets.coms offering. The analyst...

/PRNewswire/ -- The "Investigation Report on Chinas Metformin Market 2021-2025" report has been added to ResearchAndMarkets.coms offering. The analyst...

An individual filed suit on Wednesday in the Eastern District of Pennsylvania against defendant Merck & Co., Inc. (Merck) and Merck Sharp & Dohme

Born: September 17, 1929;

This randomized trial compares the effects of ivermectin vs placebo on time to symptom resolution within 21 days among patients with mild COVID-19.